Fenebrutinib, Genentech’s investigational BTK inhibitor, was found to significantly reduce relapse rates compared with the approved therapy Aubagio (teriflunomide) in two Phase 3 clinical trials involving people with relapsing forms of multiple sclerosis (MS). Positive top-line results from one of those trials, FENhance 2 (NCT04586023),…
fenebrutinib
The investigational BTK inhibitor fenebrutinib was as effective as the approved therapy Ocrevus (ocrelizumab) at reducing the risk of disability progression in people with primary progressive multiple sclerosis (PPMS), meeting the main goal of a Phase 3 trial. According to fenebrutinib’s developer, Genentech, the therapy is the…
Recommended Posts
- ‘Objective improvements’ in sleep seen with use of mindfulness in MS
- The ins, outs, ups, and downs of choosing an MS-accessible minivan
- Developer creates under-the-tongue cladribine for testing in MS
- MS treatment during pregnancy found safe for babies’ brain growth
- A springtime downpour brings back memories of my biggest supporter